Acerus Pharmaceuticals Inc. is a Toronto‐based specialty pharmaceutical company focused on the development, licensing and commercialization of innovative therapies in women’s health, endocrinology and urology. Since its founding in 1998, Acerus has built a portfolio of products designed to address unmet needs in niche markets, leveraging strategic partnerships and in‐house expertise to advance clinical candidates through regulatory approval and into patient care.
The company’s flagship asset is tesamorelin, a synthetic growth hormone‐releasing factor analog approved for the reduction of excess abdominal fat in HIV‐infected patients with lipodystrophy. Acerus retains global rights to tesamorelin and collaborates with Theratechnologies Inc. for commercialization in key territories. In women’s health, Acerus has introduced Lenzetto, a low‐dose transdermal estradiol solution for the relief of menopausal vasomotor symptoms. Additional marketed products include extended‐release formulations designed to improve patient adherence in chronic conditions.
Acerus operates primarily in North America, with regulatory approvals secured from Health Canada and the U.S. Food and Drug Administration. The company’s commercial strategy combines direct sales infrastructure in the United States with selective licensing agreements in Canada and Latin America. Ongoing research and development efforts seek to expand indications for existing products and to advance new candidates targeting conditions such as benign prostatic hyperplasia and hormone‐dependent disorders.
Led by an experienced management team and board of directors drawn from leading biopharmaceutical and clinical backgrounds, Acerus emphasizes disciplined execution and collaborative partnerships. The senior leadership team brings expertise in drug development, regulatory affairs and commercialization, having held roles at multinational pharmaceutical firms as well as successful biotech ventures. Through its focused approach and strategic alliances, Acerus aims to deliver meaningful therapeutic advances to patients and sustainable value to its stakeholders.
AI Generated. May Contain Errors.
Free ASPCF Stock Alerts